PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28591537
OWN - NLM
STAT- MEDLINE
DA  - 20170607
DCOM- 20170609
LR  - 20170614
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 23
DP  - 2017 Jun 08
TI  - Blinatumomab for Acute Lymphoblastic Leukemia.
PG  - e49
LID - 10.1056/NEJMc1704012 [doi]
FAU - Kantarjian, Hagop
AU  - Kantarjian H
AD  - University of Texas M.D. Anderson Cancer Center, Houston, TX
FAU - Jabbour, Elias
AU  - Jabbour E
AD  - University of Texas M.D. Anderson Cancer Center, Houston, TX
FAU - Topp, Max S
AU  - Topp MS
AD  - Universitatsklinikums Wurzburg, Wurzburg, Germany
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antineoplastic Agents)
RN  - 4FR53SIF3A (blinatumomab)
SB  - AIM
SB  - IM
CON - N Engl J Med. ;376(23 ):e49. PMID: 28594155
MH  - Antibodies, Bispecific/*therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
EDAT- 2017/06/08 06:00
MHDA- 2017/06/10 06:00
CRDT- 2017/06/08 06:00
AID - 10.1056/NEJMc1704012 [doi]
AID - 10.1056/NEJMc1704012#SA2 [pii]
PST - ppublish
SO  - N Engl J Med. 2017 Jun 8;376(23):e49. doi: 10.1056/NEJMc1704012.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>